5 Science Park
395 Winchester Avenue
About ArvinasArvinas is a pharmaceutical company focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Central to Arvinas’ proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. This strategy of degradation versus protein inhibition holds several advantages including the potential to target proteins that are not currently ‘druggable’ using a small molecule approach.
33 articles with Arvinas
Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants
Bayer announced a collaboration with Arvinas, Inc., a biopharmaceutical company based in New Haven, Connecticut.
4/5/2019Pharma, biotech and life science companies strengthen leadership teams, with news from Vertex, Arvinas, Provention, Enterome, and more.
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
Cedilla Therapeutics, headquartered in Cambridge, Massachusetts, launched with a $56.2 million Series A round from Third Rock Ventures.
Proceeds to advance lead oncology programs into the clinic and broaden early-stage pipeline
Arvinas closed a $55 million Series C financing round. The funds will be used to advance Arvinas’ two lead cancer programs into the clinic.
Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC ARV-110 at ASCO 2018 Genitourinary Cancers Symposium
The studies show that degradation of the androgen receptor with ARV-110 leads to inhibition of AR target gene expression and the proliferation of prostate cancer cell lines.
Pfizer will use Arvinas' proprietary PROTAC Platform to create small molecule therapeutics aimed at degrading disease-causing cellular proteins.
ARV-378 is an orally bioavailable small molecule PROTAC designed to target and induce the degradation of the estrogen receptor protein, which plays a prominent role in the development of ER positive breast cancer.
Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer Symposium
Arvinas today announced the presentation of new preclinical data for its novel oral estrogen receptor alpha PROTAC program during a poster session at the 2017 SABCS.
Under the terms of the agreement, Arvinas will access Macroceutics' DNA-Encoded chemical Libraries to identify binders to multiple targets, which have been historically undruggable through protein inhibition.
Arvinas expanded an ongoing licensing deal with Genentech.
[02-November-2017] NEW HAVEN, Conn., Nov. 2, 2017 /PRNewswire/ -- Arvinas LLC, a private biotechnology company creating a new class of small molecule drugs based on protein degradation, today announced the selection of its first candidate for clinical development as a novel treatment for metastatic castration-resistant prostate cancer (mCRPC). ARV-110 is an orally bioavailable small molecu
Arvinas Appoints Dr. John Houston As President Of Research And Development And Chief Scientific Officer
Arvinas Presents Data On Oral Estrogen Receptor PROTAC Degrader At 2016 San Antonio Breast Cancer Symposium
Arvinas Collaborators Present Data On BET PROTAC Degraders At 2016 American Society of Hematology Annual Meeting